open access

Vol 4, Supp. B (2013)
Case report
Published online: 2013-10-25
Get Citation

Nilotinib in patients with chronic myelogenous leukemia with hepatotoxicity after imatinib

Rafał Becht

open access

Vol 4, Supp. B (2013)
CASE REPORTS
Published online: 2013-10-25

Abstract

In the treatment of patients with chronic myelogenous leukemia (CML) targeted therapy with tyrosine kinase inhibitors (TKI) is used. Presently, treatment of the fi rst line is based on the three available TKI, including imatinib, nilotinib or dasatynib. However, imatinib (IM) is the most widely used in this clinical setting. In some patients, it can cause severe liver damage. This event occurs in less than 5% of patients. This paper presents a description of 2 clinical cases of hepatotoxicity after IM. In 2 patients, this was the reason of withdrawing the drug and nilotinib was introduced. The therapy was well tolerated and there was no recurrence of hepatotoxicity.

Abstract

In the treatment of patients with chronic myelogenous leukemia (CML) targeted therapy with tyrosine kinase inhibitors (TKI) is used. Presently, treatment of the fi rst line is based on the three available TKI, including imatinib, nilotinib or dasatynib. However, imatinib (IM) is the most widely used in this clinical setting. In some patients, it can cause severe liver damage. This event occurs in less than 5% of patients. This paper presents a description of 2 clinical cases of hepatotoxicity after IM. In 2 patients, this was the reason of withdrawing the drug and nilotinib was introduced. The therapy was well tolerated and there was no recurrence of hepatotoxicity.
Get Citation

Keywords

chronic myelogenous leukemia, imatinib, nilotinib, hepatotoxicity

About this article
Title

Nilotinib in patients with chronic myelogenous leukemia with hepatotoxicity after imatinib

Journal

Hematology in Clinical Practice

Issue

Vol 4, Supp. B (2013)

Article type

Case report

Pages

12-16

Published online

2013-10-25

Keywords

chronic myelogenous leukemia
imatinib
nilotinib
hepatotoxicity

Authors

Rafał Becht

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.